Debut Biotech attracts $22.6m Series A

Debut Biotech, a biomanufacturing platform harnessing cell-free enzymes, has raised $22.6 million in Series A financing.

Debut Biotech, a biomanufacturing platform harnessing cell-free enzymes, has raised $22.6 million in Series A financing. Material Impact led the round with participation from other investors that included Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures and KdT Ventures.

Source: Press Release